文献速递慢阻肺睡眠呼吸障碍

低剂量吗啡对慢阻肺患者睡眠与呼吸困难的影响:一项随机试验

The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized Trial.
PubMed 文献 · Chest · 2024-12-13

BACKGROUND: Low-dose morphine may be prescribed to reduce chronic breathlessness in COPD. Subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD.…

要点

  • 低剂量吗啡不改变慢阻肺患者睡眠效率与睡眠呼吸障碍事件频率。
  • 吗啡降低夜间氧饱和度并升高经皮CO2,夜间低通气发生率增加。
  • 吗啡未系统减轻呼吸困难或损害次日驾驶模拟表现,但不良事件增加。

核心结论

  • 稳态低剂量吗啡不改变睡眠效率、睡眠呼吸障碍频率或次日警觉性,但可能引起睡眠低通气这一潜在有害效应。

研究设计与样本

  • 随机、双盲、交叉试验,比较缓释吗啡20 mg/d用3天(稳态)与安慰剂。
  • 纳入19例有呼吸困难的慢阻肺患者,其中女性7例。
  • 主要终点为实验室过夜多导睡眠监测中的睡眠效率。

主要发现

  • 吗啡未改变睡眠呼吸障碍事件频率,但降低呼吸频率。
  • 吗啡使夜间平均氧饱和度降低2%(95%CI -2.8%至-1.2%),最低氧饱和度降低5%(95%CI -8%至-1%)。
  • 吗啡期间睡眠平均经皮CO2较安慰剂高3.3 mm Hg(95%CI 1.6-5.1 mm Hg)。

关键数值与推荐

  • 吗啡未系统性减轻呼吸困难或损害次日驾驶模拟表现。
  • 不良事件(最常见恶心)在吗啡组增加。

临床怎么用

  • 慢阻肺患者使用低剂量吗啡减轻呼吸困难时需警惕睡眠低通气风险。
  • 处方低剂量吗啡期间应关注夜间氧饱和度与经皮CO2变化。

局限性

  • 样本量较小(19例),可能限制结果外推。
  • 仅评估3天稳态低剂量吗啡,长期效应未涉及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose morphine may be prescribed to reduce chronic breathlessness in COPD. Subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD. The effects of morphine during sleep in COPD have not been objectively investigated. This study aimed to objectively determine the effects of low-dose morphine on sleep in COPD. RESEARCH QUESTION: What are the effects of low-dose morphine on sleep efficiency and other sleep parameters in COPD? STUDY DESIGN AND METHODS: This was a randomized, double-anonymized, crossover trial of sustained-release morphine (20 mg/d for 3 days) (steady-state) vs placebo in 19 breathless people with COPD (n = 7 female participants). The primary outcome was sleep efficiency during in-laboratory overnight polysomnography. Secondary and exploratory outcome measures included sleep-disordered breathing (events/h), oxygenation, transcutaneous CO2 levels, blood and physiology biomarkers, the relationship between sleep and breathlessness, external resistive load responses, and driving simulator performance. Physiology outcomes and pharmacokinetics were measured before and after each polysomnogram. RESULTS: Sleep efficiency was similar between placebo and morphine (66 ± 17% vs 67 ± 19%; P = .89). Morphine did not change the frequency of sleep-disordered breathing events but reduced breathing frequency. Morphine reduced mean and nadir overnight oxygen saturation by 2% (95% CI, -2.8% to -1.2%) and 5% (95% CI, -8% to -1%), respectively. Mean transcutaneous CO2 was 3.3 mm Hg (95% CI, 1.6-5.1 mm Hg) higher during sleep with morphine vs placebo. Eight participants (42%) met American Academy of Sleep Medicine criteria for nocturnal hypoventilation with morphine vs four (21%) receiving placebo (P = .02). Morphine did not systematically reduce breathlessness or impair next-day driving simulator performance. Adverse events (most frequently nausea) were increased with morphine. INTERPRETATION: Steady-state, low-dose morphine does not change sleep efficiency, sleep-disordered breathing frequency, or next-day alertness but may cause hypoventilation during sleep, a potentially harmful effect. CLINICAL TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry; No.: ACTRN12621000752864; URL: https://www.anzctr.org.au.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Altree TJ, Pinczel AJ, Toson B, et al. The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized Trial. Chest. 2024. PMID: 39675518. doi:10.1016/j.chest.2024.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。